Amorfix Life Sciences develops two vaccines that extend life in Amyotrophic Lateral Sclerosis (ALS) animal model



    TSX: AMF

    TORONTO, Oct. 9 /CNW/ - Amorfix Life Sciences (TSX: AMF), a company
focused on treatments and diagnostics for brain-wasting diseases, today
announced that it will be presenting the results from its vaccine development
program for Amyotrophic Lateral Sclerosis (ALS), commonly referred to as Lou
Gehrig's disease, at the 132nd Annual Meeting of the American Neurological
Association today in Washington, DC. The vaccine approach, also known as
active immunization, is the second therapeutic approach for which
proof-of-concept has been established by Amorfix for the treatment of ALS this
year. In March, Amorfix established a passive immunization approach in the
same mouse model of ALS by injecting monoclonal antibodies that target the
misfolded superoxide dismutase 1 (SOD1) protein.
    The paper entitled "Active and Passive Immunization of SOD1 Disease
Specific Epitopes in a Mouse Model of Amyotrophic Lateral Sclerosis" will be
presented by Dr. Neil Cashman, the Chief Scientific Officer of Amorfix. The
study shows for the first time life extension in a mouse model of ALS using
two vaccines targeted at different regions of the protein, termed
disease-specific epitopes, found only on the molecular surface of misfolded
SOD1.
    "These results support our original belief that specifically targeting
misfolded proteins using immunotherapies may lead to an effective treatment
for this debilitating disease, and by extension numerous other diseases such
as Parkinson's and Alzheimer's diseases," said Dr. George Adams, CEO of
Amorfix Life Sciences.
    Amorfix's targeted vaccine approach is based on the premise that the
misfolding and aggregation of SOD1, which is known to occur in familial ALS
patients, is a principal agent in the death of motor neurons in all types of
ALS disease. Amorfix believes that by administering a vaccine designed to
elicit the production of antibodies that target only misfolded SOD1, the
immune system could be educated to specifically recognize misfolded SOD1 as
foreign and neutralize it, while sparing the normally folded protein from
autoimmune recognition.
    In 2006, Amorfix and Biogen Idec entered into a research and investment
agreement that includes an option for Biogen Idec to license the exclusive
worldwide rights to Amorfix's biotherapeutics for ALS.
    In other news, Amorfix would like to thank Don McCaffrey for serving as a
Director of the Company and Chair of the Compensation Committee for the last
2 years. "Don joined the Board on the public listing of the Company and his
significant contributions have immeasurably assisted the Company to build
value over his term," said Graham Strachan, Chair of the Board.

    About Amorfix

    Amorfix Life Sciences Ltd. (TSX:AMF) is a theranostics company developing
therapeutic products and diagnostic devices targeting brain-wasting diseases
including ALS, Alzheimer's Disease, Parkinson's Disease and variant
Creutzfeldt-Jakob Disease (vCJD). Amorfix's proprietary Epitope Protection(TM)
(EP) technology enables it to specifically identify very low levels of
aggregated misfolded proteins (AMP) in a sample of normal protein. Aggregated
misfolded proteins are a common element of many brain wasting diseases and the
ability to identify AMPs and understand their structure and mechanism of
folding are the first steps to developing new treatments for these devastating
diseases. Amorfix's lead programs are a diagnostic blood screening test for
vCJD and a therapy for ALS.

    This information release may contain certain forward-looking information.
Such information involves known and unknown risks, uncertainties and other
factors that may cause actual results, performance or achievements to be
materially different from those implied by statements herein, and therefore
these statements should not be read as guarantees of future performance or
results. All forward-looking statements are based on the Company's current
beliefs as well as assumptions made by and information currently available to
it as well as other factors. Readers are cautioned not to place undue reliance
on these forward-looking statements, which speak only as of the date of this
press release. Due to risks and uncertainties, including the risks and
uncertainties identified by the Company in its public securities filings,
actual events may differ materially from current expectations. The Company
disclaims any intention or obligation to update or revise any forward-looking
statements, whether as a result of new information, future events or
otherwise.





For further information:

For further information: Dr. George Adams, President & Chief Executive
Officer, Amorfix Life Sciences Ltd., Tel: (416) 482-3813, Fax: (416) 482-3811,
george.adams@amorfix.com; James Parsons, Chief Financial Officer, Amorfix Life
Sciences Ltd., Tel: (416) 482-3814, Fax: (416) 482-3811,
james.parsons@amorfix.com

Organization Profile

Amorfix Life Sciences Ltd.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890